What Was Approved?
On July 22, 2026, the U.S. Food and Drug Administration approved Jideytro (zidesamtinib) for adults with locally advanced or metastatic ROS1-positive non-small cell lung cancer, or NSCLC, who have previously received at least one ROS1 kinase inhibitor.
Jideytro is an oral targeted cancer therapy designed for tumors driven by abnormal ROS1 signaling.
What Is ROS1-Positive NSCLC?
Non-small cell lung cancer is the most common broad category of lung cancer.
A small proportion of NSCLC tumors have a ROS1 gene alteration, which can produce abnormal signaling that promotes cancer-cell growth.
Testing the tumor for ROS1 alterations helps determine whether a ROS1-targeted therapy may be appropriate.
Who Is Jideytro Approved For?
The FDA-approved indication is specifically for adults with:
- Locally advanced or metastatic NSCLC
- A ROS1-positive tumor
- Prior treatment with a ROS1 kinase inhibitor
Jideytro is not approved as a general treatment for every type of lung cancer.
How Does Jideytro Work?
Jideytro contains zidesamtinib, a kinase inhibitor.
ROS1 alterations can activate signaling pathways that support cancer-cell growth and survival.
By inhibiting ROS1 kinase activity, zidesamtinib is intended to interfere with this abnormal signaling in ROS1-positive cancer cells.
How Is Jideytro Taken?
The FDA-approved recommended dosage is:
100 mg by mouth once daily, with or without food.
Treatment is generally continued until disease progression or unacceptable toxicity.
Patients should take the medicine exactly as prescribed and should not change the dose without guidance from their oncology team.
What Did the Clinical Study Show?
FDA evaluated Jideytro in ARROS-1, a multicenter, open-label clinical trial involving patients with previously treated locally advanced or metastatic ROS1-positive NSCLC.
The main measures of effectiveness included:
- Overall response rate, which measures how many patients had a meaningful reduction in tumor size
- Duration of response, which measures how long that response lasted
The FDA analysis included patients who had previously received one or more ROS1-targeted therapies.
What Are the Important Safety Warnings?
The FDA-approved prescribing information includes several important warnings and precautions.
Central Nervous System Effects
Jideytro can cause central nervous system adverse reactions, including:
- Dizziness
- Problems with coordination
- Cognitive changes
- Psychiatric symptoms
Depending on severity, treatment may need to be interrupted, reduced, or discontinued.
QTc Prolongation
Jideytro can prolong the QTc interval, an electrical measurement related to heart rhythm.
Healthcare professionals may evaluate risk factors and monitor patients when appropriate.
Interstitial Lung Disease or Pneumonitis
Serious inflammation of the lungs, including interstitial lung disease or pneumonitis, can occur.
New or worsening symptoms such as shortness of breath, cough, or fever should be reported promptly.
Skeletal Fractures
Fractures have occurred in patients receiving Jideytro.
Clinicians may consider bone health and symptoms suggestive of fracture during treatment.
Muscle Injury and CPK Elevation
Muscle symptoms associated with increased creatine phosphokinase, or CPK, can occur.
Patients should report significant or unexplained muscle pain or weakness.
Pancreatic Toxicity
The prescribing information also includes a warning regarding pancreatic toxicity.
Laboratory monitoring may be needed during treatment.
Are There Pregnancy Concerns?
Yes.
Based on its mechanism of action and available data, Jideytro may cause fetal harm when administered during pregnancy.
Patients who are pregnant, could become pregnant, or have a partner who could become pregnant should discuss the product’s contraception recommendations with their healthcare professional.
Are Drug Interactions Important?
Yes.
Some medications can affect Jideytro concentrations or increase the risk of adverse effects.
Patients should provide their oncology team and pharmacist with a complete list of:
- Prescription medicines
- Over-the-counter medicines
- Vitamins
- Herbal products
- Supplements
before and during treatment.
Why Is This Approval Important?
ROS1-positive NSCLC is a molecularly defined form of lung cancer, and resistance to earlier ROS1 inhibitors can limit treatment options.
Jideytro provides another FDA-approved targeted option for adults whose ROS1-positive disease has already been treated with a ROS1 kinase inhibitor.
FDA also lists Jideytro among its 2026 novel drug approvals.
Bottom Line
Jideytro (zidesamtinib) is a newly FDA-approved oral targeted therapy for adults with locally advanced or metastatic ROS1-positive non-small cell lung cancer who have previously received a ROS1 kinase inhibitor.
The recommended dose is 100 mg once daily, but treatment requires oncology supervision because significant adverse effects—including neurologic effects, QTc prolongation, lung toxicity, fractures, muscle injury, and pancreatic toxicity—can occur.
Sources
- U.S. Food and Drug Administration (FDA) — FDA Approves Zidesamtinib for ROS1-Positive Non-Small Cell Lung Cancer, July 22, 2026.
- U.S. Food and Drug Administration (FDA) — Jideytro (zidesamtinib) Prescribing Information, revised July 2026.
- U.S. Food and Drug Administration (FDA) — Novel Drug Approvals for 2026.